These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 11366562)

  • 21. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
    Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A
    J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrase and Viracept.
    Fornataro K; Jefferys R
    Body Posit; 1999 Oct; 12(10):10. PubMed ID: 11366873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The latest antiviral news.
    Vazquez E
    Posit Aware; 1999; 10(2):44. PubMed ID: 11366851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Renal transplantation in HIV-infected patients in Spain].
    Mazuecos A; Pascual J; Gómez E; Sola E; Cofán F; López F; Puig-Hooper CE; Baltar JM; González-Molina M; Oppenheimer F; Marcén R; Rivero M
    Nefrologia; 2006; 26(1):113-20. PubMed ID: 16649432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic interaction between saquinavir and cyclosporine.
    Brinkman K; Huysmans F; Burger DM
    Ann Intern Med; 1998 Dec; 129(11):914-5. PubMed ID: 9867740
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.
    Zeldin RK; Petruschke RA
    J Antimicrob Chemother; 2004 Jan; 53(1):4-9. PubMed ID: 14657084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beating HIV at its own game: the success of IL-2.
    Rochon D
    Res Initiat Treat Action; 1998 Dec; 4(7):15-6. PubMed ID: 11366082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.
    Feldt T; Oette M; Kroidl A; Göbels K; Leidel R; Sagir A; Kuschak D; Häussinger D
    Eur J Med Res; 2005 Jan; 10(1):7-10. PubMed ID: 15737947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [First-line monotherapy with boostered protease inhibitor. Effectively reduce viral load with only one drug?].
    Theobald T; Jäger H
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():28-9. PubMed ID: 16385867
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138.
    Lederman MM; Smeaton L; Smith KY; Rodriguez B; Pu M; Wang H; Sevin A; Tebas P; Sieg SF; Medvik K; Margolis DM; Pollard R; Ertl HC; Valdez H
    J Infect Dis; 2006 Dec; 194(12):1677-85. PubMed ID: 17109339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy.
    Portilla J; Boix V; Garcia-Henarejos JA; Llopis C; Martínez-Madrid O; Gimeno A; Sánchez-Paya J; Merino E
    Int J STD AIDS; 2005 Dec; 16(12):807-10. PubMed ID: 16336763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-20: new trial enrolling, 9 U.S. cities.
    James JS
    AIDS Treat News; 1998 Aug; (No 300):1-3. PubMed ID: 11365686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LaCARP seeks patients for trial of immune system builder.
    Fac Notes (New Orleans La); 1998; 10(5):4. PubMed ID: 11365834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. San Francisco: viral load trial offers free tests.
    AIDS Treat News; 1995 Sep; (no 230):7. PubMed ID: 11362762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PEP program begins in San Francisco.
    Highleyman L
    BETA; 1997 Sep; ():3. PubMed ID: 11364698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.